Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Status:
Completed
Trial end date:
2021-05-27
Target enrollment:
Participant gender:
Summary
The main purpose of the study was to investigate the clinical activity and safety of avelumab
in combination with cetuximab plus gemcitabine and cisplatin in participants with
treatment-naïve advanced squamous (NSCLC).